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Abstract
Background Empirical antibacterial therapy in hospitals
is usually guided by local epidemiologic features reflected
by institutional cumulative antibiograms. We investigated
additional information inferred by aggregating cumulative
antibiograms by type of unit or according to the place of
acquisition (i.e. community vs. hospital) of the bacteria.
Materials and methods Antimicrobial susceptibility rates
of selected pathogens were collected over a 4-year period
in an university-affiliated hospital. Hospital-wide antibio-
grams were compared with those selected by type of unit
and sampling time (\48 or[48 h after hospital admission).
Results Strains isolated [48 h after admission were less
susceptible than those presumably arising from the com-
munity (\48 h). The comparison of units revealed signifi-
cant differences among strains isolated [48 h after
admission. When compared to hospital-wide antibiograms,
susceptibility rates were lower in the ICU and surgical units
for Escherichia coli to amoxicillin-clavulanate, enterococci
to penicillin, and Pseudomonas aeruginosa to anti-pseudo-
monal beta-lactams, and in medical units for Staphylococcus
aureus to oxacillin. In contrast, few differences were
observed among strains isolated within 48 h of admission.
Conclusions Hospital-wide antibiograms reflect the sus-
ceptibility pattern for a specific unit with respect to com-
munity-acquired, but not to hospital-acquired strains.
Antibiograms adjusted to these parameters may be useful
in guiding the choice of empirical antibacterial therapy.
Keywords Antibiogram  Bacterial sensitivity tests 
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Introduction
Prompt initiation of effective antibiotic therapy has been
associated with better survival in severe hospital- or com-
munity-acquired infections [1–3]. As microbiological doc-
umentation of infection is usually obtained within 24–48 h
of symptom manifestation, the choice of empirical antibiotic
therapy is crucial in the early management of severe infec-
tions. Such an empirical therapy should provide the opti-
mized antibacterial spectrum that ensures coverage of the
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most common pathogens while avoiding the unnecessary
selection of resistant bacteria [4, 5]. The use of hospital
cumulative antibiograms (summary report of the percent-
ages of susceptible strains of a given pathogen for the anti-
biotics routinely tested in an institution) to guide the choice
of empirical antibiotic therapy has been identified as a key
strategy to prevent and control the spread of resistant
microorganisms in hospitals [4–6]. However, standardized
guidelines for the generation of these reports are currently
lacking [6]. Antimicrobial susceptibility patterns may vary
between hospitals, and differences between units within a
same institution have also been reported [7–12]. Similarly,
differences have been observed between hospital- and
community-acquired strains [13, 14].
The aim of this study was to investigate the additional
information inferred from aggregating cumulative antibi-
ograms by sampling time (\or C48 h from admission) and
type of unit within one hospital.
Materials and methods
The study was carried out at the Centre Hospitalier Uni-
versitaire Vaudois (Lausanne, Switzerland), an 850-bed
university-affiliated hospital. Data of in vitro susceptibility
testing were collected from the microbiological laboratory
over a 4-year period (2003–2006). The identification of
bacterial species and in vitro susceptibility testing were
performed according to the criteria of the American Society
for Microbiology (ASM) [15] and the breakpoints defini-
tions of the Clinical and Laboratory Standards Institute
(CLSI, Wayne, PA) [16], respectively. Antibacterial sus-
ceptibility testing for the antibiotics most commonly used
for a given microorganism were routinely performed for all
potential pathogens isolated from any sample site. Accord-
ing to the microbiological laboratory’s policy, this testing
was not repeated when a microorganism was isolated more
than once in the same patient within 4 days. Thereafter, it
was performed every 4 days (if applicable). All isolates for
whom antibacterial susceptibility testing had been per-
formed were recorded in a computer-generated database.
This system automatically excludes redundancies of strains
(same microorganism with the same antibiotic susceptibility
pattern detected in a separate isolate from a same patient).
Using this database, cumulative antibiograms were retro-
spectively calculated for each year from 2003 to 2006 for the
most frequent Gram-positive and -negative bacteria and the
antibiotics most commonly prescribed in the institution.
Some microorganisms were selected for their prevalence
and the relevance of their susceptibility pattern in the choice
of empirical antibacterial therapy: Escherichia coli (with
respect to amoxicillin/clavulanate, ciprofloxacin, ceftriax-
one), Pseudomonas aeruginosa (ceftazidime, cefepime,
imipenem, meropenem, piperacillin/tazobactam ciproflox-
acin), Staphylococcus aureus (oxacillin) and enterococci,
including Enterococcus faecium/faecalis and other Entero-
coccus spp. (penicillin; of note, no enterococci non-
susceptible to vancomycin were documented during the
study period). Antibiograms were extracted for the whole
institution and for the following units: internal medicine,
general surgery, adult intensive care (ICU) and medical
paediatrics. A distinction was made between strains
isolated \48 h or [48 h from admission (presumably
community- and hospital-acquired, respectively) [17].
Strains were differentiated as ‘‘susceptible’’ and ‘‘non-
susceptible’’ (intermediate or resistant) according to the
breakpoints definitions of the CLSI [16].
Susceptibility rates were compared between presumably
community- and hospital-acquired strains and between the
whole hospital and the units mentioned above. Differences
between susceptibility rates aggregated by the site of
sampling (blood cultures vs. cultures from any other site)
were also investigated. Fisher’s exact test was used to
compare proportions. Two-sided p values \0.05 were
considered as statistically significant. Because of the large
number of statistical comparisons, Bonferroni corrections
for multiple tests were applied.
Results
Of the total number of strains analysed for the whole
institution during the study period, 11,485 (44.5% hospital-
acquired) were E. coli strains, 4,638 (72.6% hospital-acquired)
were P. aeruginosa strains, 3,405 (65% hospital-acquired)
were enterococci strains and 8,008 (50.9% hospital-
acquired) were S. aureus strains.
Annual hospital-wide susceptibility rates of these
pathogens remained stable over the 4-year period (\5%
variation over time for all of the antibiotics tested). Anti-
biograms calculated for the 4-year period were thus con-
sidered in further analyses.
For the whole institution, susceptibility rates were sig-
nificantly lower for strains isolated C48 h from admission
when compared to those isolated\48 h (p value\0.001 for
all pathogen/antibiotic combinations) (Table 1).
Among presumably community-acquired strains (iso-
lated \48 h from admission), antibiograms calculated for
specific units displayed few differences when compared to
those of the whole institution. The most relevant differ-
ences were observed for P. aeruginosa susceptibility to
ciprofloxacin in medical and surgical units (64 vs. 80%,
p \ 0.001 and 62 vs. 80%, p = 0.01, respectively), and to
imipenem in surgical units (71 vs. 87%; p = 0.01). In
contrast, major differences between units were observed
among hospital-acquired strains (Fig. 1a, b). P. aeruginosa
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susceptibility rates to most anti-pseudomonal beta-lactams
were lower in surgical units and ICU than those calculated
for the whole institution, while medical and paediatric units
displayed similar or higher susceptibility rates (Fig. 1a). In
addition, susceptibility of enterococci to penicillin was
lower in ICU and surgical units (70 vs. 86% for the whole
institution, p \ 0.001) and susceptibility of E. coli to
amoxicillin/clavulanate was lower in surgical units (70 vs.
81%, p \ 0.001). The susceptibility of S. aureus to oxa-
cillin was lower in medical units (70 vs. 84%, p \ 0.001)
(Fig. 1b).
The distinction according to the site of sampling (blood
vs. any site) showed no differences above 5% in suscep-
tibility rates, with the exception of P. aeruginosa suscep-
tibility to piperacillin/tazobactam (85 vs. 92% for blood
cultures and cultures from any site, respectively,
p = 0.015) and ciprofloxacin (86 vs. 72%, p = 0.001), and
enterococci susceptibility to penicillin (82 vs. 90%,
p = 0.002).
Discussion
The results of our analysis revealed significant differences
in antimicrobial susceptibility rates between presumably
hospital- and community-acquired strains. These differ-
ences were particularly relevant for P. aeruginosa. The
comparison between different units showed similar sus-
ceptibility rates among community-acquired strains,
whereas important differences were observed among hos-
pital-acquired strains, especially for P. aeruginosa and
enterococci and with respect to the prevalence of
methicillin-resistance in S. aureus (MRSA). However,
stratification according to the site of sampling for cultures
added little additional relevant information. These findings
may have an impact on the choice of empirical antibiotic
therapy, although it is limited to a subset of clinical situ-
ations and specific for the hospital where the data were
collected.
Variability in the susceptibility rates between units in a
same hospital has been reported previously [7–12]. Most
differences were observed between the ICUs and non-
ICUs. However, little data are available on the comparison
of cumulative antibiograms between wards other than ICUs
and according to the sampling time in terms of being able
to distinguish presumably nosocomial from community-
acquired infections [7, 13, 14]. The study presented here
proposes an integration of these easily available parame-
ters. The potential impact of such a focused approach on
the control of the emergence of resistance has been sug-
gested in earlier studies [5, 18]. It should, however, be
specified that the use of cumulative antibiograms aggre-
gated according to ward or sampling time would only be
possible if they are derived from a large enough number of
isolates to reach statistical significance (provided that
susceptibility rates remain stable over the time needed to
obtain this number of isolates). Statistical significance is
not enough, however, and unit- or sampling time-specific
data should only be provided if they show clinically rele-
vant gaps in antibiotic susceptibility. It may be the task of a
hospital antibiotic committee to assess this relevance.
Resistance of P. aeruginosa to carbapenems is an
important problem in ICUs and has been associated with
exposure to this class of antibiotics [19–21]. Similarly,
Table 1 Comparison of the
rates of susceptibility to selected
antibiotics between presumably
community- and hospital-
acquired strains
Values are given as the number
of susceptible strains/total
number of strains, with the
percentage of total in
parenthesis
a p value \ 0.001 for all
comparisons between
community- and hospital-
acquired strains
Microorganisms and
selected antibiotics to
which they showed susceptibility
Community-acquired strains
(\48 h from admission)
Hospital-acquired strains
([48 h from admission)a
Escherichia coli
Amoxicillin/clavulanate 5,672/6,370 (89) 4,146/5,111 (81)
Ceftriaxone 6,301/6,372 (99) 4,940/5,113 (97)
Ciprofloxacin 5,860/6,348 (92) 4,342/5,091 (85)
Pseudomonas aeruginosa
Cefepime 1,179/1,269 (93) 2,807/3,368 (83)
Ceftazidime 1,148/1,269 (90) 2,638/3,368 (78)
Imipenem 1,100/1,269 (87) 2,389/3,368 (71)
Meropenem 1,157/1,269 (91) 2,703/3,367 (80)
Piperacillin/tazobactam 1,215/1,269 (96) 3,039/3,368 (90)
Ciprofloxacin 1,015/1,269 (80) 2,309/3,369 (69)
Staphylococcus aureus
Oxacillin 3,670/3,931 (93) 3,439/4,077 (84)
Enterococci
Penicillin 1,151/1,192 (97) 1,904/2,214 (86)
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a low susceptibility rate of P. aeruginosa to carbapenems
was observed among ICU isolates in our analysis. Data on
antimicrobial consumption in our institution revealed that
the use of carbapenems was particularly high in the ICU
[22 defined daily dose (DDD)/100 bed-days for both imi-
penem and meropenem when compared to 4.5 for pipera-
cillin/tazobactam, whereas carbapenems consumption in
the whole institution was only 4 DDD/100 bed-days] [22].
The use of amoxicillin and amoxicillin/clavulanate in
surgical units was also higher than that in medical units
(22.4 and 14.3 DDD/100 bed-days, respectively), which
may contribute to the lower susceptibility rate of entero-
cocci to penicillin in the former setting.
This analysis has several limitations. First, it was con-
ducted in a single centre. As such, these results may not be
reproducible in other countries or institutions depending on
potential differences in case-mix and epidemiologic char-
acteristics. Differences observed in the prevalence of
MRSA may particularly result from variations in the case-
mix between units or from possible cross-infections. In
addition, individual risk factors for infections with resistant
microorganisms, such as the duration of hospital stay,
underlying diseases or previous antibacterial therapy, are
not taken into account by such an approach based on
aggregated data from the microbiology lab. However, the
utility of cumulative antibiograms for guiding local
empirical antibiotic strategies and preventing the emer-
gence of resistance has been clearly established despite this
intrinsic limitation [5]. Second, the 48-h cutoff was chosen
according to the Centers for Disease Control standard
definitions of nosocomial infections [17]. However, the
incubation period of infection may vary according to the
type of pathogen or the patient’s underlying conditions,
making the distinction between hospital- and community-
acquired infections difficult to determine in some cases
[17]. This may be of particular relevance for P. aeruginosa.
Third, our data do not allow differentiating bacteria iso-
lated in true infections from those considered to be colo-
nizers or contaminants. However, such a distinction should
not have resulted in significant differences in susceptibility
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Fig. 1 Comparison of
susceptibility rates between
units within a same hospital for
selected microorganism/
antibiotic combinations in
hospital-acquired strains
(culture drawn [48 h from
admission). x axis Percentage of
susceptible strains, black bars
medical units, white bars
surgical units, dark-grey bars
intensive care units, light-grey
bars pediatric units, black
vertical lines susceptibility rate
for the whole hospital. Numbers
on the right p value (Fisher’s
exact test with application of
Bonferroni corrections for
multiple tests) for the
comparison between unit-
specific and hospital-wide
susceptibility rates, NS not
significant (p [ 0.05).
a Pseudomonas aeruginosa
and cefepime, ceftazidime,
ciprofloxacin, imipenem,
meropenem and piperacillin/
tazobactam, b Staphylococcus
aureus and oxacillin,
Escherichia coli and
amoxicillin/clavulanate and
ciprofloxacin, enterococci
(Enterococcus faecalis/faecium
and other enterococci species)
and penicillin
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rates. Finally, the repetition of antimicrobial susceptibility
testing for a same strain isolated in a same patient may
have been a source of bias despite the use of selection
criteria to avoid such redundancies in our electronic data-
base. One of the consequences is the impossibility to dis-
tinguish between primary or secondary acquired resistance.
In conclusion, the results of the analysis reported here
suggest that hospital-wide cumulative antibiograms reflect
the actual susceptibility pattern for a specific unit with
regard to community-acquired infection, but not with
regard to hospital-acquired infections. Institutional policies
for the report of cumulative antibiograms should thus be
adapted to these parameters that are easy to obtain. Such an
approach may be useful in guiding the choice of empirical
antibacterial therapy.
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